These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 32840305

  • 1. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
    Deemer K, Grey J, Fronczek C, Marr K.
    Am J Health Syst Pharm; 2020 Nov 16; 77(Supplement_4):S105-S110. PubMed ID: 32840305
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, Kang TW, Kwon DD, Park K.
    Int Urol Nephrol; 2015 Jul 16; 47(7):1059-66. PubMed ID: 26026972
    [Abstract] [Full Text] [Related]

  • 3. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
    Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, Arda B, Ulusoy S.
    J Chemother; 2010 Oct 16; 22(5):355-7. PubMed ID: 21123160
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Abe Y, Inan-Erdogan I, Fukuchi K, Wakabayashi H, Ogawa Y, Hibino S, Sakurai S, Matsuhashi K, Watanabe Y, Hashimoto K, Ugajin K, Itabashi K.
    J Infect Chemother; 2017 Aug 16; 23(8):517-522. PubMed ID: 28528936
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis.
    Senard O, Lafaurie M, Lesprit P, Nguyen Y, Lescure X, Therby A, Fihman V, Oubaya N, Lepeule R.
    Eur J Clin Microbiol Infect Dis; 2020 Jan 16; 39(1):121-129. PubMed ID: 31512147
    [Abstract] [Full Text] [Related]

  • 7. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
    Auer S, Wojna A, Hell M.
    Antimicrob Agents Chemother; 2010 Sep 16; 54(9):4006-8. PubMed ID: 20585127
    [Abstract] [Full Text] [Related]

  • 8. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S, Gençer S, Batırel A, Hacıseyitoğlu D, Ozer S.
    Mikrobiyol Bul; 2014 Oct 16; 48(4):545-55. PubMed ID: 25492650
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
    Zykov IN, Samuelsen Ø, Jakobsen L, Småbrekke L, Andersson DI, Sundsfjord A, Frimodt-Møller N.
    Antimicrob Agents Chemother; 2018 Jun 16; 62(6):. PubMed ID: 29581117
    [Abstract] [Full Text] [Related]

  • 11. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P, Boroumand MA, Rahbar M, Douraghi M.
    Microb Drug Resist; 2018 Jun 16; 24(5):607-612. PubMed ID: 29064348
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
    Rodríguez-Avial C, Rodríguez-Avial I, Hernández E, Picazo JJ.
    Rev Esp Quimioter; 2013 Mar 16; 26(1):43-6. PubMed ID: 23546462
    [Abstract] [Full Text] [Related]

  • 14. Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection.
    Xie O, Cisera K, Taylor L, Hughes C, Rogers B.
    Ann Clin Microbiol Antimicrob; 2020 Nov 30; 19(1):57. PubMed ID: 33256752
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases.
    Bahramian A, Eslami G, Hashemi A, Tabibi A, Heidary M.
    Acta Microbiol Immunol Hung; 2018 Mar 01; 65(1):15-25. PubMed ID: 29137487
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Park SH, Choi SM, Chang YK, Lee DG, Cho SY, Lee HJ, Choi JH, Yoo JH.
    J Antimicrob Chemother; 2014 Oct 01; 69(10):2848-56. PubMed ID: 24928854
    [Abstract] [Full Text] [Related]

  • 19. Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive Escherichia coli and Klebsiella pneumoniae Isolated From Urine of Pediatric Patients.
    Park KS, Kim DR, Baek JY, Shin A, Kim KR, Park H, Son S, Cho H, Kim YJ.
    J Korean Med Sci; 2023 Dec 11; 38(48):e361. PubMed ID: 38084025
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.